TABLE 3.

Association of sAGEs at Baseline with Development of Vascular Health.

Parameter	CRAE at follow-up (µm change per unit increase)		CRVE at follow-up (µm change per unit increase)		AVR at follow-up (Units change per unit increase)		PWV at follow-up (m/s change per unit increase)
	β (95% CI)	p-Value	β (95% CI)	p-Value	β (95% CI)	p-Value	β (95% CI)	p-Value
sAGEs at baseline (au) a	−3.99 (−7.03 to −0.96)	0.010	−1.49 (−4.87 to 1.88)	0.386	−0.01 (−0.03 to 0.001)	0.070	0.02 (−0.07–0.12)	0.658

Parameter	∆ CRAE (µm change per unit increase)		∆ CRVE (µm change per unit increase)		∆ AVR (Units change per unit increase)		∆ PWV (m/s change per unit increase)
	β (95% CI)	p-Value	β (95% CI)	p-Value	β (95% CI)	p-Value	β (95% CI)	p-Value
sAGEs at baseline (au) b	−5.42 (−8.76 to −2.08)	0.001	−2.98 (−6.63 to 0.66)	0.109	−0.01 (−0.27 to 0.002)	0.088	0.07 (−0.07–0.2)	0.329

sAGEs, skin autofluorescence-derived advanced glycation end products; AVR, indicates arteriolar-to-venular diameter ration; BMI, body mass index; CRAE, central retinal arteriolar equivalent; CRVE, central retinal venular equivalent; PWV, pulse wave velocity.

^a Adjusted for sex, vascular parameter at baseline (CRAE, CRVE, AVR, or PWV) and SBP, age at follow-up.

^b Adjusted for sex at baseline and SBP, age at follow-up.